MyoCell, MyoCell SDF-1 and MyoCath are trademarks of Bioheart, Inc.
Except for historical matters contained herein, statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.
Investors and others are cautioned that a variety of factors, including
certain risks, may affect our business and cause actual results to differ
materially from those set forth in the forward-looking statements. These
risk factors include, without limitation, (i) our ability to secure
additional financing; (ii) the timely success and completion of our
clinical trials; (iii) the occurrence of any unacceptable side effects
during or after preclinical and clinical testing of our product candidates;
(iv) regulatory approval of our product candidates; (v) our dependence on
the success of our lead product candidate; (vi) our inability to predict
the extent of our future losses or if or when we will become profitable;
(vii) our ability to protect our intellectual property rights; and (viii)
intense competition. The Company is also subject to the risks and
uncertainties described in its filings with the Securities and Exchange
Commission, including the section entitled "Risk Factors" in its Annual
Report on Form 10-K for the year ended December 31, 2007, as amended by
Amendment No. 1 on Form 10-K/A and its quarterly report on Form 10-Q for
the quarter ended March 31, 2008.
Contact: William Kline
|SOURCE Bioheart, Inc.|
Copyright©2008 PR Newswire.
All rights reserved